Amgen Czech Republic's operating cash flow stood at CZK 118 mil in 2017, up 1% when compared to the previous year. Historically, between 2006 - 2017, the firm’s operating cash flow reached a high of CZK 130 mil in 2015 and a low of CZK -43.7 mil in 2014.
Amgen Czech Republic's total investments stood at CZK -58.4 mil and accounted for 0.032% of sales in 2017. This is compared to an average of 0.108% as seen over the last five years.
Cash from financing amounted to CZK -60.0 mil, so the company generated CZK 0.014 mil net cash in 2017.
At the end of 2017, the company had a net debt of CZK -0.283 mil, or -0.006x of EBITDA and -0.147% of equity. Net working capital amounted to CZK 248 mil, or 59.6% of sales. Cash conversion cycle is negative and reached 211 days days in 2017. This means Amgen Czech Republic generates revenue from customers before it has to pay its suppliers for inventory, among other things.
You can see all the company’s data at Amgen Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
